An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
Status:
Completed
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
This integrated assessment consists of two studies, 603A and 603B, to be carried out
sequentially in a common study population. Participating subjects informed of the trial
design and their consent to participate in both studies were to be obtained in a single
consent form. Approximately 680 male or female adult subjects were to be enrolled.